U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846606) titled 'Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS' on Feb. 06.
Brief Summary: This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed Acute Myeloid Leukemia (AML)
Refractory Acute Myeloid Leukemia (AML)
Relapsed/refractory AML
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes
Relapsed/R...